Abstract 244P
Background
Non clear cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumors; usually treated with immunotherapy (IO) and or tyrosine kinase inhibitors (TKI). Prospective large-scale data from Asia specific countries is limited. We aimed to present the demographic profile and treatment outcome of nccRCC patients from single centre in India.
Methods
This is a retrospective study on patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata-West Bengal from 2012-2022. Demographic profiles, histologic subtypes, treatment details, response to therapy (by RECIST v1.1) and survival status were captured from electronic medical records of hospitals up till March 2023. Progression free survival (PFS) and Overall survival (OS) were estimated using Kaplan Meier method.
Results
A total of 89 patients were screened;24 excluded due to inadequate records. 65 patients were included in analysis, with a median age at diagnosis of 59 years (range 20-84). Histologic subtypes comprised 43% (n=28) papillary, 31%(n=20) clear cell with mixed histology, 3%(2) sarcomatoid & 23%(15) others including chromophobe, oncocytoma. The most common site of metastasis was lung 62% (n=40).15% presented with haematuria and 62%(n=40) underwent cytoreductive nephrectomy. Majority received pazopanib 46% (n=30) then chemotherapy 20% (n=13) including bevacizumab plus erlotinib, sunitinib 15%(10), cabozantinib 14%(9). Only 3(5%) received IO plus TKI combination. The best response was CR in 1.5%, PR 20%, SD 51% & PD 23% as per RECIST v1.1. Total 17 (26%) patients required dose reduction & interruption due to adverse effects & 33% received second-line therapy with nivolumab,axitinib & everolimus were commonly used. After a median follow up of 44 months; median PFS was 13 months (95%CI 7.2-18.9) & median OS was 17 months (95%CI 12.1-22.1). Regression analysis identified better outcome for PFS & OS with sarcomatoid subtype & those underwent prior nephrectomy.
Conclusions
The overall response and survival was quite impressive in comparison with published data; despite limited number of cases treated with IO due to its cost.This study also highlighted better survival with sarcomatoid subtype and prior nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract